Dr. Wang is Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center. He has published more than 270 peer-reviewed papers and has presented his work at meetings nationally and internationally. He is the Director of the Mantle Cell Lymphoma (MCL) Program of Excellence, Co-Director of Clinical Trials, and PI of the B-cell Lymphoma Moon Shot Program at MD Anderson. During the past 22 years, he has focused on both preclinical and clinical research. He established the first human primary MCL animal model for the study of the biology and treatment of MCL. He pioneered work to improve the treatment of patients with MCL, including the introduction of BTK inhibitors such as ibrutinib, acalabrutinib, and pirtobrutinib in the treatment algorithm, and has performed extensive work with CAR-T cells for the treatment of patients who relapsed on other therapies. His work has been published in the most prestigious medical journals, such as the New England Journal of Medicine and The Lancet.